Trials / Terminated
TerminatedNCT00697593
ChangE From Any Systemic psoriasiS therapY to Raptiva
A Phase IV Open Label Study in Moderate to Severe Chronic Plaque Psoriasis Subjects Transitioning From Previous Systemic Antipsoriasis Therapies (Methotrexate, Cyclosporine, Retinoids or Psoralen-Ultraviolet Light A (PUVA), Narrow-Band Ultraviolet Light B (NBUVB) to Raptiva 1mg/kg/ Week Therapy.
- Status
- Terminated
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 70 (actual)
- Sponsor
- Merck KGaA, Darmstadt, Germany · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
To assess the safety of transitioning subjects to Raptiva therapy from standard oral systemic or phototherapy by overlapping with Raptiva whilst tapering the initial systemic therapy or phototherapy dose.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Efalizumab - anti CD11a recombinant human monoclonal antibody (mAb) | Each subject will receive an initial conditioning dose of 0.7 mg/kg/week and then will continue treatment at a dose of 1mg/kg/week for up to 12 weeks. |
Timeline
- Start date
- 2008-01-01
- Primary completion
- 2009-04-01
- Completion
- 2009-04-01
- First posted
- 2008-06-16
- Last updated
- 2014-02-13
- Results posted
- 2010-08-30
Locations
1 site across 1 country: Canada
Source: ClinicalTrials.gov record NCT00697593. Inclusion in this directory is not an endorsement.